Related Experiment Video
Updated: Jun 21, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Alternative splicing and biological heterogeneity in prostate cancer
Prabhakar Rajan1, David J Elliott, Craig N Robson
1Beatson Institute for Cancer Research, Glasgow, UK. p.rajan@beatson.gla.ac.uk
Abstract:
The biological diversity of prostate cancer confounds standardization of therapy. Advances in molecular profiling suggest that differences in the genetic composition of tumors significantly contribute to the complexity of the disease. Alternative pre-mRNA splicing is a key genetic process underlying biological diversity. During alternative splicing, coding and noncoding regions of a single gene are rearranged to generate several messenger RNA transcripts yielding distinct protein isoforms with differing biological functions. Misregulation of the splicing machinery and mutations in key regulatory elements affect splicing of cancer-relevant genes. In prostate cancer, aberrant and alternative splicing generates proteins that influence cell phenotypes and survival of patients. Splicing events may be exploited for clinical benefit, and technological advances are beginning to uncover novel biomarkers and therapeutic targets. Since splicing mediates information transfer from the genome to the proteome, it adds an important dimension to '-omics'-based molecular signatures used to individualize care of patients.
Insights
Prostate cancer's complexity arises from genetic differences, particularly alternative splicing. Understanding these splicing changes can reveal new biomarkers and treatments for personalized prostate cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer exhibits significant biological diversity, complicating treatment standardization.
- Genetic variations, especially in tumor composition, contribute to disease complexity.
- Alternative pre-messenger RNA (pre-mRNA) splicing is a crucial genetic mechanism driving biological diversity.
Purpose of the Study:
- To explore the role of alternative splicing in prostate cancer's biological diversity.
- To identify how aberrant splicing influences cancer-relevant genes and protein isoforms.
- To highlight the potential of splicing events as clinical biomarkers and therapeutic targets.
Main Methods:
- Analysis of molecular profiling data in prostate cancer.
- Investigation of pre-mRNA splicing machinery and regulatory elements.
- Examination of genetic mutations affecting splicing in cancer-relevant genes.
Main Results:
- Alternative splicing generates distinct protein isoforms with varied biological functions.
- Misregulation of splicing machinery and mutations impact cancer-relevant gene splicing.
- Aberrant splicing in prostate cancer produces proteins affecting cell phenotypes and patient survival.
Conclusions:
- Alternative splicing is a key factor in prostate cancer's heterogeneity and complexity.
- Splicing events offer potential for developing novel biomarkers and therapeutic strategies.
- Splicing-mediated genomic information transfer provides a new dimension for '-omics'-based personalized medicine in prostate cancer.
More Related Videos
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...

